Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines

Kuo Hsiang Chuang, Chiu Min Cheng, Steve R. Roffler, Yu Lin Lu, Shiu Ru Lin, Jaw Yuan Wang, Wen Shyong Tzou, Yu Cheng Su, Bing Mae Chen, Tian Lu Cheng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells. Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo. Dansyl moieties were covalently attached to recombinant β-glucuronidase (βG) and interleukin 2 (IL-2) via a flexible polyethylene glycol) linker to form DNS-PEG-βG and DNS-PEG-IL-2 conjugates. The conjugates displayed enzymatic and splenocyte-stimulatory activities, respectively, that were similar to those of the unmodified proteins. The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells). DNS-PEG-βG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration. Systemic administration of DNS-PEG-IL-2 or DNS-PEG-βG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors. Combination treatment with DNS-PEG-βG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen. These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
JournalBioconjugate Chemistry
Volume17
Issue number3
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Haptens
Prodrugs
Polyethylene glycols
Enzymes
Cytokines
Tumors
Interleukin-2
Neoplasms
Aniline Mustard
Therapeutics
Cells
Single-Chain Antibodies
Glucuronidase
Glucuronides
Cell membranes
Growth
Intravenous Administration
Colonic Neoplasms
Aniline
Antibodies

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Chuang, K. H., Cheng, C. M., Roffler, S. R., Lu, Y. L., Lin, S. R., Wang, J. Y., ... Cheng, T. L. (2006). Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjugate Chemistry, 17(3), 707-714. https://doi.org/10.1021/bc0600160

Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. / Chuang, Kuo Hsiang; Cheng, Chiu Min; Roffler, Steve R.; Lu, Yu Lin; Lin, Shiu Ru; Wang, Jaw Yuan; Tzou, Wen Shyong; Su, Yu Cheng; Chen, Bing Mae; Cheng, Tian Lu.

In: Bioconjugate Chemistry, Vol. 17, No. 3, 05.2006, p. 707-714.

Research output: Contribution to journalArticle

Chuang, KH, Cheng, CM, Roffler, SR, Lu, YL, Lin, SR, Wang, JY, Tzou, WS, Su, YC, Chen, BM & Cheng, TL 2006, 'Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines', Bioconjugate Chemistry, vol. 17, no. 3, pp. 707-714. https://doi.org/10.1021/bc0600160
Chuang, Kuo Hsiang ; Cheng, Chiu Min ; Roffler, Steve R. ; Lu, Yu Lin ; Lin, Shiu Ru ; Wang, Jaw Yuan ; Tzou, Wen Shyong ; Su, Yu Cheng ; Chen, Bing Mae ; Cheng, Tian Lu. / Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. In: Bioconjugate Chemistry. 2006 ; Vol. 17, No. 3. pp. 707-714.
@article{c9852bd676f8415a84fc10cdb31687c5,
title = "Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines",
abstract = "Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells. Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo. Dansyl moieties were covalently attached to recombinant β-glucuronidase (βG) and interleukin 2 (IL-2) via a flexible polyethylene glycol) linker to form DNS-PEG-βG and DNS-PEG-IL-2 conjugates. The conjugates displayed enzymatic and splenocyte-stimulatory activities, respectively, that were similar to those of the unmodified proteins. The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells). DNS-PEG-βG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration. Systemic administration of DNS-PEG-IL-2 or DNS-PEG-βG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors. Combination treatment with DNS-PEG-βG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen. These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.",
author = "Chuang, {Kuo Hsiang} and Cheng, {Chiu Min} and Roffler, {Steve R.} and Lu, {Yu Lin} and Lin, {Shiu Ru} and Wang, {Jaw Yuan} and Tzou, {Wen Shyong} and Su, {Yu Cheng} and Chen, {Bing Mae} and Cheng, {Tian Lu}",
year = "2006",
month = "5",
doi = "10.1021/bc0600160",
language = "English",
volume = "17",
pages = "707--714",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines

AU - Chuang, Kuo Hsiang

AU - Cheng, Chiu Min

AU - Roffler, Steve R.

AU - Lu, Yu Lin

AU - Lin, Shiu Ru

AU - Wang, Jaw Yuan

AU - Tzou, Wen Shyong

AU - Su, Yu Cheng

AU - Chen, Bing Mae

AU - Cheng, Tian Lu

PY - 2006/5

Y1 - 2006/5

N2 - Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells. Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo. Dansyl moieties were covalently attached to recombinant β-glucuronidase (βG) and interleukin 2 (IL-2) via a flexible polyethylene glycol) linker to form DNS-PEG-βG and DNS-PEG-IL-2 conjugates. The conjugates displayed enzymatic and splenocyte-stimulatory activities, respectively, that were similar to those of the unmodified proteins. The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells). DNS-PEG-βG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration. Systemic administration of DNS-PEG-IL-2 or DNS-PEG-βG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors. Combination treatment with DNS-PEG-βG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen. These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.

AB - Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells. Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo. Dansyl moieties were covalently attached to recombinant β-glucuronidase (βG) and interleukin 2 (IL-2) via a flexible polyethylene glycol) linker to form DNS-PEG-βG and DNS-PEG-IL-2 conjugates. The conjugates displayed enzymatic and splenocyte-stimulatory activities, respectively, that were similar to those of the unmodified proteins. The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells). DNS-PEG-βG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration. Systemic administration of DNS-PEG-IL-2 or DNS-PEG-βG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors. Combination treatment with DNS-PEG-βG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen. These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.

UR - http://www.scopus.com/inward/record.url?scp=33646942955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646942955&partnerID=8YFLogxK

U2 - 10.1021/bc0600160

DO - 10.1021/bc0600160

M3 - Article

C2 - 16704208

AN - SCOPUS:33646942955

VL - 17

SP - 707

EP - 714

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 3

ER -